WO1984001108A1 - Means for removing microorganisms from tissue - Google Patents
Means for removing microorganisms from tissue Download PDFInfo
- Publication number
- WO1984001108A1 WO1984001108A1 PCT/SE1983/000323 SE8300323W WO8401108A1 WO 1984001108 A1 WO1984001108 A1 WO 1984001108A1 SE 8300323 W SE8300323 W SE 8300323W WO 8401108 A1 WO8401108 A1 WO 8401108A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fragment
- protein
- residue
- microorganisms
- tissue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
Definitions
- the present invention concerns means for removing micro orgartisms from tissue, such as mucous membranes, skin and wound tissue.
- microorganisms Gram-positive bacteria, such as different species of staphylococci, streptococci and pneumococci, Sram-positive rods, such as mycobac teria, e.g. Mycobacterium leprae, Gram-negative bacteria, such as different species of the family Enterobacteriaceae, e.g. Escherichia coli, Klebsiella, Proteus, Enterobacter or Vibrio nacae, or Pseudomonas, as well as Gram-negative cocci, such as gonococci.
- This expression also includes anaerobic bacteria, such as Bacteroides, fusobacteria, anaerobic cocci, e.g.
- pep tococci and peptostreptococci as well as spirillae and spirochetes.
- fungi such as Candida, e.g. Candida albicans, and dermatophytes, as well as pathogenic amoebae, such as Entam ⁇ eba histolytica, and Giardia Lamblia and Leishmania.
- the ways of removing microorganisms from tissue vary due to type of tissue and microorganism, respectively.
- a disinfectant or antibiotic is often used for removing pathogenic microorganisms from mucous membranes and skin tissue.
- a drawback with this is that the indigenous flora is removed as well, and thus the functions it serves.
- Further drawbacks are that disinfectants are cell toxic and that today many pathogenic strains have developed resistence against a large number of antibiotics.
- the removal of pathogenic microorganisms from wound tissue is carried out in several ways. One way is a direct attack on the microorganisms by treatment with disinfectants or antibiotics, but this is unefficient and results in the above mentioned drawbacks the indigenous flora.
- Another way is mechanical cleaning of wound tissue by means of moist saline dressings.
- the drawbacks with this are i.a. that the tissue healing is inhibited and that such dressings must be changed very often.
- the latter is an example of a more indirect way of removing pathogenic microorganisms from wound tissue.
- the secretions from the wound tissue are excellent substrate for microorganisms, and by reducing the amount thereof the growth of the microorganisms will also be decreased.
- Other methods wherein this indirect way is used are treatment of wounds by means of suitable polymers, e.g. in particle form , which polymers absorb the secretions from the wound tissue.
- Some of these secretion-absorbing polymers contain comp l ex ly bound iod ine (so ca l led iodo phores ) , and with these a secretion-absorption and a disinfection are simultaneously achieved.
- the present invention concerns means for removing microorganisms from tissue without influencing the indigenous flora in any greater extent.
- a predominant cause of primary wound infections and postsurgical infections are certain Gram-positive cocci, such as Staphylococcus aureus and so called ⁇ -hemolysing streptococci from group A, C and G.
- Pathogenic staphylococci exist everywhere in the environment, also that of a hospital where up to 80 % of the personnel can be carriers of pathogens.
- Yellow staphylococci colonize especially in certain parts of the skin, such as the axilla, the bottom of the pelvis and on the hand as well as in the nose. Even in dry eczema there is a frequent existence of white as well as yellow staphylococci.
- the common tonsillitis bacteria Streptococcus pyogenes Cgroup A streptococcus exists in a high frequency on nursing personnel as well as patients.
- Nosocomial infections are often transferred exogenic (from e.g. personnel to a patient) or endogenic (patients having these microorganisms on skin or mucous membranes infect their own wounds) and this has became an increasing problem.
- classical preventive steps have so far been taken, such as careful pre-surgical cleaning and bandaging of infected eczema in separate rooms.
- the first step in most infection processes is the binding of the microorganism to tissue.
- the microorganisms bind specifically, either direct to a component on the surface of the epithelium cell or to extracellular molecules in blood clot or in connective tissue being exposed to the microorganisms in an epithelium wound.
- the present invention is based upon a completely new principle for removing microorganisms from tissue, which principle is based upon inhibition of the binding of the microorganisms to the tissue proteins on mucous membranes, skin and in wounds.
- Pathogenic staphylococci have on their cell surface a protein (protein A) that specifically binds to the complement binding site (Fc-site) of immunoglobulins of different classes in a great number of animal species. This binding specificity is used in immunological tests and for removal of antibodies in extracorporal circulation by means of protein A bound to a solid phase.
- protein A protein A
- Fc-site complement binding site
- staphylococci are agglutinated by normal serum from different animal species. This reaction is due to a specific binding between the surface of the bacteria and fibrin/fibrinogen.
- proteins or fragments or residues thereof are suitable means for removing microorganisms from tissue.
- the present invention thus concerns means for removing av microorganisms from tissue, such as mucous membranes, skin and wound tissue, which means comprises at least one protein or a fragment or residue thereof which can be bound to the microorganisms, and optionally a carrier to which the protein or fragment or residue thereof is bound.
- Suitable proteins to be used in accordance with the invention are fibrinogen, fibronectin, an immunoglobulin, albumin, haptoglobin, ⁇ -2-microglobulin, collagen, laminin, e ⁇ tactin or chondronectin. Further, fragments or residues of these proteins are also suitable. These fragments or residues can be peptides having a molecular weight of 5x10 2 - 10 5 , preferably
- Suitable carriers to be used in accordance with the invention are polymer materials, such as agarose or a derivative thereof, starch or a derivative thereof, cellulose or a derivative thereof, dextran or a derivative thereof, or an alginate. Further, a fiber material being a part of absorption products, such as a dressing or a tampon, is also suitable.
- Proteins or fragment(s) or residue(s) thereof can be bound to the carrier in a manner known per se, and that through a covalent bond via the carbohydrate part, the primary amino groups, the sulfhydryl or the carboxy groups in the protein, e.g. by means of divinyl sulfon, epichlorohydrin, carbodiimide, by means of transamination or via cyanobromide bridges, or by biospecific interactions known per se, such as the binding of fibronectin to gelatin, the binding of glycoproteins to lectin or the binding of antigens to antibodies.
- the proteins or fragments or residues thereof can also be absorbed directly on a carrier.
- the present invention is further illustrated in the following exar ⁇ ples;
- Example 1 Skin areas on human loin was washed with a physio logical saline solution. Then about 10 7 and 10 9 Staphylococcus aureus (strain Newman) were applied on several skin areas.
- the fibronectin had been bound to a cyanobromide activated gel of Sepharose ®
- Example_2 Example 1 was repeated, but instead of strain Newman Staphylococcus aureus (strain V 8) was used. The same type of control gel was also used. The cultivation check after the completed treatment showed a growth of strain V 8 that was considerably larger than that for strain Newman of example 1.
- Example 3 Example 1 was repeated, but instead of fibronectin fibrinogen was used. The binding of fibrinogen to the gel of Sepharose ® 4B was established in the same manner as for fibronectin in example 1. A gel of pure Sepharose ® 4B was used as a control gel.
- strain Newman has a fibronectin receptor whereas strain V 8 is bound very weakly to fibronectin, but has a fibrinogen receptor. It is further evident that a strain having a Fn receptor is removed specifically.
- Example 1 was repeated using Staphylococcus aureus, strain SA 113 and strain Cowan 1, and group A streptococci, strain H 15757 and strain 11270.
- the proteins used were albumin, immun ⁇ globulin G, fibrinogen and fibronectin, respectively, and these were bound to a gel of Sepharose 4B in the same way as was fibronectin in example 1. In all the examples gel of pure Sepharose ® 4B was used as a control gel.
- Staphylococcus aureus (strain SA 113) was cultivation negative (only single colonies of bacteria were observed), whereas positive cultivation results of this strain were obtained when albumin, immunoglobulin G and fibrinogen, respectively, were used.
- Staphylococcus aureus (strain Cowan 1) was cultivation negative when immunoglobulin G, fibrinogen and fibronectin, respectively, was used, whereas positive cultivation results of this strain were obtained when albumin was used.
- Group A streptococcus (strain H 15757) was cultivation negative wjnen albumin and fibronectin, respectively, were used, whereas positive cultivation results of this strain were obtained when immunoglobulin G and fibrinogen, respectively, were used.
- Group A streptococcus (strain 11270) was cultivation negative when fibrinogen was used, whereas positive cultivation results of this strain were obtained when albumin, immunoglobulin G and fibronectin, respectively, were used.
- ExampIe_20 Hospital personnel with a recognized colonisation of antibiotic resistent Staphylococcus aureus were divided into two groups , each of the same size (test and control group, respectively). Samples from all persons in the two groups exhibited repeated positive cultivation results.
- the test group was treated with cotton swabs, that had been dipped in a fibronectin solution, which swabs were plugged in the nostrils and kept there for a couple of hours, whereafter they were exchanged with fresh swabs, also being dipped in the fibronectin solution. The procedure was repeated so that the treatment was carried out totally 3 times.
- the control group was treated in the same way, but unprepared swabs were used.
- mice (20 - 30 g , CBA strain) were shaved and subjected to a second or third degree burn according to an international standard on an area of 1x1 cm (ethanol flame, 2 minutes).
- Staphylococcus aureus strain Cowan 1
- Suspensions of 10 microorganisms per ml saline solution phosphate buffered was prepared and all mice were painted with 0.5 ml of the suspension on the burnt area . The mice were then divided into a test and a control group.
- mice of the test group were treated with fibronectin bounded to a gel of Sepharose ® 4B whereas the mice of the control group were treated with pure Sepharose ® 4B.
- the treatment was carried out so that the gel was app l ied to the burnt area in a confluent layer being about 2-3 mm thick.
- mice in the test group were cultivation negative (i.e. 1-3 colonies) after 1 day.
- Samples from mice in the control group were cultivation positive (more than 3 colonies up ta confluent growth) still after 3 days.
- ExampIe 22 The same type of mice as those of example 21 was used. Instead of S.aureus Staphylococcus capitis, LK 499 was used, but besides that the procedure of example 21 was repeated.
- mice in the test group were cultivation positive on day 2, whereas samples from mice in the control group were cultivation positive still on day 4.
- ExampIe 23 The same type of mice as those of example 21 was used. Instead of S. auerues Staphylococcus haemolyticus was used, but besides that the procedure of example 21 was repeated.
- Example 24 The same procedure and strain as in examples 21
- mice in the test group were used and also the same type of mice, but the mice in the test group were treated with fibrinogen bound to a gel of Sepharose ® 4B. Samples from mice in the test group were cultivation negative on day 2, whereas samples from mice in the control group were cultivation positive on day 4.
- ExampIe 25 The same procedure and strain as in example 22 were used and also the same type of mice, but the mice of the test group were treated with fibrinogen bound to a gel of Sepharose ® 4B.
- ExampIe 26 The same procedure and strain as in example 23 were used and also the same type of mice, but the mice in the test group were treated with fibrinogen bound to a gel of Sepharose ® 4B.
- the proteins can also be bound to fiber materials being a part of an absorption product, such as dressings or tampons in orde ⁇ r to remove microorganisms from wound or other tissue. Dressings, to which the proteins are bound are suitable for the treatment of wounds. Tampons to which a protein has been bound can e.g. be used in surgery for absorbing from surgical wounds, or as catamenial tampans, where they can be used for removing the microorganisms being the cause of the so called tampon disease.
- the means of the present invention can also be used for removing microorganisms in wound hollows, who e.g. are the result of an opening of abscesses, such as anal abscesses, in which case the means preferably is bound to a dressing having the shape of the wound hollow in order to fill this up and to inhibit the closing of the abscess.
- a dressing material can e.g. be in fiber or granular form in an absorption material enclosed in a hydrofobic material.
- the protein can further be in the form of a rinsing solution for removing of microorganisms in local infections.
Abstract
Means for removing microorganisms from tissue, such as mucous membranes, skin and wound tissue, which means comprises at least one protein or fragment(s) or residue(s) thereof which can be bound to the microorganisms, and optionally a carrier to which the protein(s) or the fragment(s) or residue(s) thereof is bound. The invention further concerns use of protein(s) or fragment(s) thereof for removing of microorganisms from tissue.
Description
MEANS FOR REMOVING MICROORGANISMS FROM TISSUE
The present invention concerns means for removing micro orgartisms from tissue, such as mucous membranes, skin and wound tissue.
On skin and mucous membranes there is an indigenous flora of non-pathogenic as well as potentially pathogenic microorganisms. The presence of the indigenous flora serves certain useful functions and can prevent colonisation of pathogenic microorganisms. Someone who in this way carries pathogenic microorganisms is a potential carrier of pathogens as the pathogenic microorganisms from such a person can be transferred to a tissue wound.
With the expression microorganisms is meant Gram-positive bacteria, such as different species of staphylococci, streptococci and pneumococci, Sram-positive rods, such as mycobac teria, e.g. Mycobacterium leprae, Gram-negative bacteria, such as different species of the family Enterobacteriaceae, e.g. Escherichia coli, Klebsiella, Proteus, Enterobacter or Vibrio nacae, or Pseudomonas, as well as Gram-negative cocci, such as gonococci. This expression also includes anaerobic bacteria, such as Bacteroides, fusobacteria, anaerobic cocci, e.g. pep tococci and peptostreptococci, as well as spirillae and spirochetes. Further included are fungi, such as Candida, e.g. Candida albicans, and dermatophytes, as well as pathogenic amoebae, such as Entamσeba histolytica, and Giardia Lamblia and Leishmania.
The ways of removing microorganisms from tissue vary due to type of tissue and microorganism, respectively. For removing pathogenic microorganisms from mucous membranes and skin tissue a disinfectant or antibiotic is often used. A drawback with this is that the indigenous flora is removed as well, and thus the functions it serves. Further drawbacks are that disinfectants are cell toxic and that today many pathogenic strains have developed resistence against a large number of antibiotics. The removal of pathogenic microorganisms from
wound tissue is carried out in several ways. One way is a direct attack on the microorganisms by treatment with disinfectants or antibiotics, but this is unefficient and results in the above mentioned drawbacks the indigenous flora. Another way is mechanical cleaning of wound tissue by means of moist saline dressings. The drawbacks with this are i.a. that the tissue healing is inhibited and that such dressings must be changed very often. The latter is an example of a more indirect way of removing pathogenic microorganisms from wound tissue. The secretions from the wound tissue are excellent substrate for microorganisms, and by reducing the amount thereof the growth of the microorganisms will also be decreased. Other methods wherein this indirect way is used are treatment of wounds by means of suitable polymers, e.g. in particle form , which polymers absorb the secretions from the wound tissue. Some of these secretion-absorbing polymers contain comp l ex ly bound iod ine (so ca l led iodo phores ) , and with these a secretion-absorption and a disinfection are simultaneously achieved.
The present invention concerns means for removing microorganisms from tissue without influencing the indigenous flora in any greater extent.
A predominant cause of primary wound infections and postsurgical infections are certain Gram-positive cocci, such as Staphylococcus aureus and so called β-hemolysing streptococci from group A, C and G. Pathogenic staphylococci exist everywhere in the environment, also that of a hospital where up to 80 % of the personnel can be carriers of pathogens. Yellow staphylococci (S.aureus) colonize especially in certain parts of the skin, such as the axilla, the bottom of the pelvis and on the hand as well as in the nose. Even in dry eczema there is a frequent existence of white as well as yellow staphylococci. The common tonsillitis bacteria Streptococcus pyogenes Cgroup A streptococcus) exists in a high frequency on nursing personnel as well as patients. Nosocomial infections are often transferred exogenic (from e.g. personnel to a patient) or endogenic (patients having these microorganisms on skin or
mucous membranes infect their own wounds) and this has became an increasing problem. In order to decrease the frequency of these infections classical preventive steps have so far been taken, such as careful pre-surgical cleaning and bandaging of infected eczema in separate rooms.
The first step in most infection processes is the binding of the microorganism to tissue. The microorganisms bind specifically, either direct to a component on the surface of the epithelium cell or to extracellular molecules in blood clot or in connective tissue being exposed to the microorganisms in an epithelium wound.
The present invention is based upon a completely new principle for removing microorganisms from tissue, which principle is based upon inhibition of the binding of the microorganisms to the tissue proteins on mucous membranes, skin and in wounds.
Pathogenic staphylococci have on their cell surface a protein (protein A) that specifically binds to the complement binding site (Fc-site) of immunoglobulins of different classes in a great number of animal species. This binding specificity is used in immunological tests and for removal of antibodies in extracorporal circulation by means of protein A bound to a solid phase.
It is also known that staphylococci are agglutinated by normal serum from different animal species. This reaction is due to a specific binding between the surface of the bacteria and fibrin/fibrinogen.
It has now been found that receptors like those being present in staphylococci also exist in other microorganisms. Frequence studies on e.g. strains of staphylococci and streptococci isolated from wound infections and other types of infections show that the ability of binding e.g. fibronectin is contributing to the virulence of the microorganisms. In infections caused e.g. by Staphylococcus aureus and coagulase negative staphylococci this binding ability contributes to the
virulence by making an initial tissue colonisation passible.
Surprisingly it has now been found that proteins or fragments or residues thereof, optionally bound to a carrier, are suitable means for removing microorganisms from tissue. The present invention thus concerns means for removing av microorganisms from tissue, such as mucous membranes, skin and wound tissue, which means comprises at least one protein or a fragment or residue thereof which can be bound to the microorganisms, and optionally a carrier to which the protein or fragment or residue thereof is bound.
Suitable proteins to be used in accordance with the invention are fibrinogen, fibronectin, an immunoglobulin, albumin, haptoglobin, β-2-microglobulin, collagen, laminin, eπtactin or chondronectin. Further, fragments or residues of these proteins are also suitable. These fragments or residues can be peptides having a molecular weight of 5x102 - 105 , preferably
5x102 - 5x104 .
Suitable carriers to be used in accordance with the invention are polymer materials, such as agarose or a derivative thereof, starch or a derivative thereof, cellulose or a derivative thereof, dextran or a derivative thereof, or an alginate. Further, a fiber material being a part of absorption products, such as a dressing or a tampon, is also suitable.
Proteins or fragment(s) or residue(s) thereof can be bound to the carrier in a manner known per se, and that through a covalent bond via the carbohydrate part, the primary amino groups, the sulfhydryl or the carboxy groups in the protein, e.g. by means of divinyl sulfon, epichlorohydrin, carbodiimide, by means of transamination or via cyanobromide bridges, or by biospecific interactions known per se, such as the binding of fibronectin to gelatin, the binding of glycoproteins to lectin or the binding of antigens to antibodies.
The proteins or fragments or residues thereof can also be absorbed directly on a carrier.
The present invention is further illustrated in the following exarηples; Example 1: Skin areas on human loin was washed with a physio logical saline solution. Then about 107 and 109 Staphylococcus aureus (strain Newman) were applied on several skin areas. A gel of Sepharose® 4B, to which fibronectin had been bound, was applied to the skin areas on which strain Newman had been applied, and that in 2 - 3 mm thick layers. The fibronectin had been bound to a cyanobromide activated gel of Sepharose®
48 by incubating 10 mg of fibronectin per ml cyanobromide activated gel for 2 h at room temperature and under a gentle stirring. The reaction was terminated by adding 1M glyoine solution to the reaction mixture, whereafter the incubation was continued for further 30 minutes. Before use the gel was thoroughly washed. Pure Sepharose® 4B was used as control gel and applied in the same manner on the other skin areas on which strain Newman had been applied. All skin areas were dried with a fan (cold air). After 20-30 minutes test gel as well as control gel were removed by a sterile scalpel. Ther after fresh material of both gels were applied and the procedure was repeated until totally 3 treatments had been carried out, and that during a period of time of about 2 h.
After the completed procedure cultivation shows that strain Newman had been removed almost completely (only single colonies of bacteria were observed) whereas cultivations from skin areas where control gel had been applied only showed a small decrease in bacteria number.
Example_2: Example 1 was repeated, but instead of strain Newman Staphylococcus aureus (strain V 8) was used. The same type of control gel was also used. The cultivation check after the completed treatment showed a growth of strain V 8 that was considerably larger than that for strain Newman of example 1.
Example 3: Example 1 was repeated, but instead of fibronectin fibrinogen was used. The binding of fibrinogen to the gel of
Sepharose® 4B was established in the same manner as for fibronectin in example 1. A gel of pure Sepharose® 4B was used as a control gel.
Cultivation after the completed procedure shows that strain V 8 had been almost completely removed ( only single colonies were observed) while cultivations from skin areas being treated with control gel only showed a small decrease in bacteria number.
These examples show that strain Newman has a fibronectin receptor whereas strain V 8 is bound very weakly to fibronectin, but has a fibrinogen receptor. It is further evident that a strain having a Fn receptor is removed specifically.
ExampIes_4_-_1_9: Example 1 was repeated using Staphylococcus aureus, strain SA 113 and strain Cowan 1, and group A streptococci, strain H 15757 and strain 11270.
The proteins used were albumin, immunσglobulin G, fibrinogen and fibronectin, respectively, and these were bound to a gel of Sepharose 4B in the same way as was fibronectin in example 1. In all the examples gel of pure Sepharose® 4B was used as a control gel.
The procedure described in example 1 was carried out and subsequent cultivation showed the hereinafter given results for the different organisms and proteins, respectively.
When fibronectin was used Staphylococcus aureus (strain SA 113) was cultivation negative (only single colonies of bacteria were observed), whereas positive cultivation results of this strain were obtained when albumin, immunoglobulin G and fibrinogen, respectively, were used.
Staphylococcus aureus (strain Cowan 1) was cultivation negative when immunoglobulin G, fibrinogen and fibronectin, respectively, was used, whereas positive cultivation results of this strain were obtained when albumin was used.
Group A streptococcus (strain H 15757) was cultivation negative wjnen albumin and fibronectin, respectively, were used, whereas positive cultivation results of this strain were obtained when immunoglobulin G and fibrinogen, respectively, were used.
Group A streptococcus (strain 11270) was cultivation negative when fibrinogen was used, whereas positive cultivation results of this strain were obtained when albumin, immunoglobulin G and fibronectin, respectively, were used.
Cultures from skin areas where control gel had been applied gave in all cases positive cultivation results.
ExampIe_20: Hospital personnel with a recognized colonisation of antibiotic resistent Staphylococcus aureus were divided into two groups , each of the same size (test and control group, respectively). Samples from all persons in the two groups exhibited repeated positive cultivation results. The test group was treated with cotton swabs, that had been dipped in a fibronectin solution, which swabs were plugged in the nostrils and kept there for a couple of hours, whereafter they were exchanged with fresh swabs, also being dipped in the fibronectin solution. The procedure was repeated so that the treatment was carried out totally 3 times. The control group was treated in the same way, but unprepared swabs were used.
Samples from the persons in the control group after the completion procedure were cultivation positive, whereas samples from the persons in the test group were completely negative.
Ex.amgle_21: Mice (20 - 30 g , CBA strain) were shaved and subjected to a second or third degree burn according to an international standard on an area of 1x1 cm (ethanol flame, 2 minutes). Staphylococcus aureus (strain Cowan 1) was used as microorgaism in this example. Suspensions of 10 microorganisms per ml saline solution (phosphate buffered) was prepared and all mice were painted with 0.5 ml of the suspension on the
burnt area . The mice were then divided into a test and a control group. The mice of the test group were treated with fibronectin bounded to a gel of Sepharose® 4B whereas the mice of the control group were treated with pure Sepharose® 4B. The treatment was carried out so that the gel was app l ied to the burnt area in a confluent layer being about 2-3 mm thick.
After removing of one layer by scraping with a scalpel a fresh layer was applied, and the treatment was repeated until totally three layers of gel had been applied and removed. Then samples were taken from the burnt area, which samples were cultivated.
Samples from mice in the test group were cultivation negative (i.e. 1-3 colonies) after 1 day. Samples from mice in the control group were cultivation positive (more than 3 colonies up ta confluent growth) still after 3 days.
ExampIe 22: The same type of mice as those of example 21 was used. Instead of S.aureus Staphylococcus capitis, LK 499 was used, but besides that the procedure of example 21 was repeated.
Samples from mice in the test group were cultivation positive on day 2, whereas samples from mice in the control group were cultivation positive still on day 4.
ExampIe 23: The same type of mice as those of example 21 was used. Instead of S. auerues Staphylococcus haemolyticus was used, but besides that the procedure of example 21 was repeated.
Samples from mice in the test as well as control group were cultivation positive after day 3.
Example 24: The same procedure and strain as in examples 21
were used and also the same type of mice, but the mice in the test group were treated with fibrinogen bound to a gel of Sepharose® 4B.
Samples from mice in the test group were cultivation negative on day 2, whereas samples from mice in the control group were cultivation positive on day 4.
ExampIe 25 : The same procedure and strain as in example 22 were used and also the same type of mice, but the mice of the test group were treated with fibrinogen bound to a gel of Sepharose ®4B.
Samples from mice in the test as well as the control group were cultivation positive after 4 days.
ExampIe 26: The same procedure and strain as in example 23 were used and also the same type of mice, but the mice in the test group were treated with fibrinogen bound to a gel of Sepharose ®4B.
Samples from mice in the test as well as the control group were cultivation positive after 4 days.
From the examples is evident that different microorganisms bind to different proteins. The bindings shown between the microorganism and protein, respectively, have been confirmed by in vitro experiments. These have been carried out by incubating respectively microorganism with respectively protein, the latter being labelled with radioactive iodine. After completed incubation the amount of radioactively labelled proteins bound to respective microorganism was measured. In those cases where the microorganisms have been removed by the treatment with a protein (cultivation negative samples), in vitro experiments have proved that respective microorganism has been bound to the radioactively labelled protein, whereas in those cases where the microorganisms have not been removed (cultivation positive samples) after the treatment with a protein, in vitro experiments have proved that there is no bond between the corresponding microorganism and radioactively labelled protein.
The proteins can also be bound to fiber materials being a part of an absorption product, such as dressings or tampons in ordeαr to remove microorganisms from wound or other tissue. Dressings, to which the proteins are bound are suitable for the treatment of wounds. Tampons to which a protein has been bound can e.g. be used in surgery for absorbing from surgical wounds, or as catamenial tampans, where they can be used for removing the microorganisms being the cause of the so called tampon disease.
The means of the present invention can also be used for removing microorganisms in wound hollows, who e.g. are the result of an opening of abscesses, such as anal abscesses, in which case the means preferably is bound to a dressing having the shape of the wound hollow in order to fill this up and to inhibit the closing of the abscess. Such a dressing material can e.g. be in fiber or granular form in an absorption material enclosed in a hydrofobic material. The protein can further be in the form of a rinsing solution for removing of microorganisms in local infections.
Claims
1. Means for removing microorganisms from tissue, such as mucous membranes, skin and wound tissue, characterized in that it comprises at least one protein or fragment(s) or residue(s) thereof which can be bound to the microorganisms, and optionally a carrier to which the protein(s) or the fragment(s) or residue(s) thereof is bound.
2. The means of claim 1, characterized in that the protein or fragment(s) or residue(s) thereof is fibrinogen, fibronectin, an immunoglobulin, albumin, haptoglobin, β-2-microglo bulin, collagen, laminin, entactin or chondronectin.
3. The means of claim 1, characterized in that the fragment(s) or residue(s) of the protein(s) is derived from fibrinogen, fibronectin, an immunoglobulin, albumin, haptoglobin, β-2-microglobulin, collagen, laminin, entactin or chodronectin.
4. The means of claim 3, characterized in that the fragment ment(s) or residue(s) is a peptide having a molecular weight of 5xl02-105.
5. The means of any of the claims 1-4, characterized in that the carrier is a polymer material, such as agarose or a derivative thereof, starch or a derivative thereof, cellulose or a derivative thereof, dextrane or a derivative thereof or an alginate.
6. The means of any of the claims 1-4, characterized in that the carrier consists of a fibrous material being a part of absorption products, such as a dressing or a tampon.
7. The means of any of the claims 1-6, characterized in that the protein(s) or the fragment(s) or residue(s) thereof is linked/bound to the carrier by means of divinyl sulfon, epichlorohydrin, carbodiimid b means of transamination, via cyanobromide bridges or by biospecific interaction.
8. The means of any of the claims 1-6, characterized in that the protein(s) or the fragment(s) or residue(s) thereof is absorbed on the carrier.
9. Use of proteins, such as fibrinogen, fibronectin, an immunoglobulin, albumin, haptoglobin, β-2-microg lobul in , collagen, laminin, entactin or chondroπectin, or fragments or residues thereof of for removing of microorganisms from tissue, such as mucous membranes, skin and wound tissue.
10, The use of proteins or fragment(s) or residue(s) thereof according to claim 9, characterized in that the protein(s) or fragment(s) or residue(s) thereof is bound to or absorbed on a carrier.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE8383902918T DE3377198D1 (en) | 1982-09-14 | 1983-09-13 | Means for removing microorganisms from tissue |
AT83902918T ATE35380T1 (en) | 1982-09-14 | 1983-09-13 | AGENT FOR REMOVING MICROORGANISMS FROM TISSUE. |
DK234784A DK160231C (en) | 1982-09-14 | 1984-05-11 | USE OF PROTEIN FOR THE PREPARATION OF AN AGENT FOR THE REMOVAL OF MICROORGANISMS FROM WEAVES |
NO841901A NO164639C (en) | 1982-09-14 | 1984-05-11 | USE OF PROTEIN FOR THE PREPARATION OF AN AGENT FOR THE REMOVAL OF MICRO ORGANISMS FROM WEBS. |
FI841936A FI841936A0 (en) | 1982-09-14 | 1984-05-14 | MEDEL FOER AVLAEGSNANDE AV MICROORGANISM FRAON VAEVNADER. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8205244A SE446688C (en) | 1982-09-14 | 1982-09-14 | Means for the removal of microorganisms from tissues, which consist of a protein that can be bound to the microorganisms |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1984001108A1 true WO1984001108A1 (en) | 1984-03-29 |
Family
ID=20347843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1983/000323 WO1984001108A1 (en) | 1982-09-14 | 1983-09-13 | Means for removing microorganisms from tissue |
Country Status (7)
Country | Link |
---|---|
US (1) | US4784989A (en) |
EP (1) | EP0119233B1 (en) |
JP (1) | JPS59501745A (en) |
DE (1) | DE3377198D1 (en) |
DK (1) | DK160231C (en) |
SE (1) | SE446688C (en) |
WO (1) | WO1984001108A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0160521A2 (en) * | 1984-04-25 | 1985-11-06 | Green Cross Corporation | Fibronectin-dextran-drug complex and method of preparation thereof |
WO1986003937A1 (en) * | 1985-01-10 | 1986-07-17 | Chemical Dynamics Sweden Ab | Method of detaching micro-flora and compositions therefor |
EP0214392A1 (en) * | 1985-07-02 | 1987-03-18 | Omni Medical Limited | Medical device. especially a filter, cannula, catheter or an implant |
WO1992003172A1 (en) * | 1990-08-17 | 1992-03-05 | Sebapharma Gmbh & Co. | Dressing system |
EP0549239A1 (en) * | 1991-12-24 | 1993-06-30 | Wako Pure Chemical Industries Ltd | Process for extracting endotoxin |
DE19813663A1 (en) * | 1998-03-27 | 1999-10-07 | Beiersdorf Ag | Wound dressings for removing disruptive factors from wound fluid |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5189015A (en) * | 1984-05-30 | 1993-02-23 | Alfa-Laval Agri International Ab | Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability |
SE8801894D0 (en) * | 1988-05-20 | 1988-05-20 | Alfa Laval Agri Int | FIBRONECT BINING PROTEIN |
US4973466A (en) * | 1988-06-21 | 1990-11-27 | Chiron Ophthalmics, Inc. | Wound-healing dressings and methods |
US5070889A (en) * | 1988-10-13 | 1991-12-10 | Leveen Harry H | Contraceptive sponge and tampon |
US5000749A (en) * | 1988-10-13 | 1991-03-19 | Leveen Harry H | Iodine contraceptive sponge |
US5156164A (en) * | 1988-10-13 | 1992-10-20 | Leveen Harry H | Iodine contraceptive sponge |
SE8901687D0 (en) * | 1989-05-11 | 1989-05-11 | Alfa Laval Agri Int | FIBRONECTIN BINDING PROTEIN AS WELL AS IT'S PREPARATION |
US5440014A (en) * | 1990-08-10 | 1995-08-08 | H+E,Uml/Oo/ K; Magnus | Fibronectin binding peptide |
US5980908A (en) * | 1991-12-05 | 1999-11-09 | Alfa Laval Ab | Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment |
JPH08508240A (en) * | 1993-01-12 | 1996-09-03 | ジョージ グリスティーナ,アンソニー | Methods and compositions for direct transfer of passive immunity |
US7112320B1 (en) | 1995-06-07 | 2006-09-26 | Andre Beaulieu | Solid wound healing formulations containing fibronectin |
US6685943B1 (en) | 1997-01-21 | 2004-02-03 | The Texas A&M University System | Fibronectin binding protein compositions and methods of use |
JP2003507440A (en) * | 1999-08-20 | 2003-02-25 | アンドレ・ボウリウ | Solid wound healing composition containing fibronectin |
US6309454B1 (en) | 2000-05-12 | 2001-10-30 | Johnson & Johnson Medical Limited | Freeze-dried composite materials and processes for the production thereof |
US6773723B1 (en) * | 2000-08-30 | 2004-08-10 | Depuy Acromed, Inc. | Collagen/polysaccharide bilayer matrix |
US7115264B2 (en) * | 2001-11-05 | 2006-10-03 | Inhibitex | Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2422308A1 (en) * | 1974-03-07 | 1975-09-18 | Ici Australia Ltd | Polymer film wound dressing - contg. protein, pref. casein (salt), and moisture-retainer, and opt. formed in situ. |
DE2635508A1 (en) * | 1975-08-06 | 1977-02-10 | John Bunyan | ANTISEPTIC BODY |
CH590660A5 (en) * | 1973-01-29 | 1977-08-15 | Pharmacia Ab | |
DE2725261A1 (en) * | 1977-06-03 | 1978-12-14 | Max Planck Gesellschaft | Transparent liq. gels e.g. of hydrophilic acrylic! polymer and gelatin - useful as wound dressings, esp. for burns and ulcers, and as cell culture media |
DE2823620A1 (en) * | 1977-06-09 | 1979-01-11 | Pikok Ind Trading Co | COLLAGEN SKIN DRESSING MATERIAL |
DE3002038A1 (en) * | 1979-01-22 | 1980-07-31 | Ernest Aubrey Woodroof | ORGANIC AND BLOOD COMPATIBLE MATERIALS AND METHOD FOR THE PRODUCTION THEREOF |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1594389A (en) * | 1977-06-03 | 1981-07-30 | Max Planck Gesellschaft | Dressing material for wounds |
AT371723B (en) * | 1978-11-15 | 1983-07-25 | Max Planck Gesellschaft | TRANSPARENT LIQUID BANDAGE MATERIAL, AND METHOD FOR THE PRODUCTION THEREOF |
JPS571266A (en) * | 1980-06-02 | 1982-01-06 | Sanyo Electric Co Ltd | Solar cell |
DE3105624A1 (en) * | 1981-02-16 | 1982-09-02 | Hormon-Chemie München GmbH, 8000 München | MATERIAL FOR SEALING AND HEALING Wounds |
JPS57140724A (en) * | 1981-02-25 | 1982-08-31 | Green Cross Corp:The | Heat-treatment of aqueous solution containing cold insoluble globulin |
ATE20824T1 (en) * | 1981-06-25 | 1986-08-15 | Serapharm Gmbh & Co Kg | ENRICHED PLASMA DERIVES TO SUPPORT WOUND CLOSURE AND HEALING. |
ATE13810T1 (en) * | 1981-06-25 | 1985-07-15 | Serapharm Gmbh & Co Kg | ENRICHED PLASMA DERIVES TO ASSIST WOUND CLOSURE AND COVERAGE. |
US4478829A (en) * | 1983-04-28 | 1984-10-23 | Armour Pharmaceutical Company | Pharmaceutical preparation containing purified fibronectin |
-
1982
- 1982-09-14 SE SE8205244A patent/SE446688C/en not_active IP Right Cessation
-
1983
- 1983-09-13 JP JP58503006A patent/JPS59501745A/en active Granted
- 1983-09-13 DE DE8383902918T patent/DE3377198D1/en not_active Expired
- 1983-09-13 WO PCT/SE1983/000323 patent/WO1984001108A1/en active IP Right Grant
- 1983-09-13 EP EP83902918A patent/EP0119233B1/en not_active Expired
- 1983-09-13 US US06/611,000 patent/US4784989A/en not_active Expired - Lifetime
-
1984
- 1984-05-11 DK DK234784A patent/DK160231C/en not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH590660A5 (en) * | 1973-01-29 | 1977-08-15 | Pharmacia Ab | |
DE2422308A1 (en) * | 1974-03-07 | 1975-09-18 | Ici Australia Ltd | Polymer film wound dressing - contg. protein, pref. casein (salt), and moisture-retainer, and opt. formed in situ. |
DE2635508A1 (en) * | 1975-08-06 | 1977-02-10 | John Bunyan | ANTISEPTIC BODY |
DE2725261A1 (en) * | 1977-06-03 | 1978-12-14 | Max Planck Gesellschaft | Transparent liq. gels e.g. of hydrophilic acrylic! polymer and gelatin - useful as wound dressings, esp. for burns and ulcers, and as cell culture media |
DE2849570A1 (en) * | 1977-06-03 | 1980-06-04 | Max Planck Gesellschaft | TRANSPARENT LIQUID ASSOCIATION MATERIAL |
DE2823620A1 (en) * | 1977-06-09 | 1979-01-11 | Pikok Ind Trading Co | COLLAGEN SKIN DRESSING MATERIAL |
DE3002038A1 (en) * | 1979-01-22 | 1980-07-31 | Ernest Aubrey Woodroof | ORGANIC AND BLOOD COMPATIBLE MATERIALS AND METHOD FOR THE PRODUCTION THEREOF |
Non-Patent Citations (1)
Title |
---|
Rompps Chemie-Lexikon, 8 Aufl. (1981), Bd. 2, p. 1280-81 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0160521A2 (en) * | 1984-04-25 | 1985-11-06 | Green Cross Corporation | Fibronectin-dextran-drug complex and method of preparation thereof |
EP0160521A3 (en) * | 1984-04-25 | 1986-12-10 | Green Cross Corporation | Fibronectin-dextran-drug complex and method of preparation thereof |
WO1986003937A1 (en) * | 1985-01-10 | 1986-07-17 | Chemical Dynamics Sweden Ab | Method of detaching micro-flora and compositions therefor |
EP0214392A1 (en) * | 1985-07-02 | 1987-03-18 | Omni Medical Limited | Medical device. especially a filter, cannula, catheter or an implant |
WO1992003172A1 (en) * | 1990-08-17 | 1992-03-05 | Sebapharma Gmbh & Co. | Dressing system |
EP0549239A1 (en) * | 1991-12-24 | 1993-06-30 | Wako Pure Chemical Industries Ltd | Process for extracting endotoxin |
US5346889A (en) * | 1991-12-24 | 1994-09-13 | Wako Pure Chemical Industries, Ltd. | Process for extracting endotoxin |
DE19813663A1 (en) * | 1998-03-27 | 1999-10-07 | Beiersdorf Ag | Wound dressings for removing disruptive factors from wound fluid |
US6156334A (en) * | 1998-03-27 | 2000-12-05 | Beiersdorf, Ag | Wound coverings for removal of interfering factors from wound fluid |
Also Published As
Publication number | Publication date |
---|---|
JPS59501745A (en) | 1984-10-18 |
JPH0549302B2 (en) | 1993-07-23 |
DK160231B (en) | 1991-02-18 |
SE446688B (en) | 1986-10-06 |
DK234784A (en) | 1984-05-11 |
SE8205244D0 (en) | 1982-09-14 |
EP0119233A1 (en) | 1984-09-26 |
DK160231C (en) | 1991-07-22 |
EP0119233B1 (en) | 1988-06-29 |
US4784989A (en) | 1988-11-15 |
DE3377198D1 (en) | 1988-08-04 |
SE8205244L (en) | 1984-03-15 |
SE446688C (en) | 1989-08-01 |
DK234784D0 (en) | 1984-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4784989A (en) | Means for removing microorganisms from tissue | |
EP1496919B1 (en) | Immobilisation and stabilisation of virus | |
US4570629A (en) | Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same | |
JPH08508240A (en) | Methods and compositions for direct transfer of passive immunity | |
US5331092A (en) | Process of preparation of collagen containing in major proportion insoluble collagen and collagen having high mechanical resistance and thermal stability obtained thereby | |
CA1067408A (en) | Antiseptic compositions | |
Naidu et al. | Particle agglutination assays for rapid detection of fibronectin, fibrinogen, and collagen receptors on Staphylococcus aureus | |
JPH0747541B2 (en) | Cell surface protein, its production method and its use | |
Tachi et al. | Comparison of bacteria‐retaining ability of absorbent wound dressings | |
EP0621044A2 (en) | Collagen membranes | |
JP2000508620A (en) | Methods and compositions for passive immunotherapy | |
JPS5888316A (en) | Wound treating composition, manufacture and use | |
Hedström | The prognosis of chronic staphylococcal osteomyelitis after long-term antibiotic treatment | |
US5034515A (en) | Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use | |
GB2240040A (en) | Immobilised enzyme-containing wound dressings | |
RU2113476C1 (en) | Strain of bacteriophage of pseudomonas aeruginosa "гнц пм" n 02 used for preparing mixed curative preparation against pyocyanic coli | |
AU679786B2 (en) | A topical antibacterial preparation | |
Cheung et al. | Role of surface proteins in staphylococcal adherence to fibers in vitro. | |
Dineen | The in vivo production of penicillinase by hemolytic Staphylococcus aureus | |
NO164639B (en) | USE OF PROTEIN FOR THE PREPARATION OF AN AGENT FOR THE REMOVAL OF MICRO ORGANISMS FROM WEBS. | |
Roberts et al. | Activity of antibiotics in contaminated wounds containing clay soil | |
CA2464889A1 (en) | Cytokine-inducing material and cytokine-inducing instrument | |
JP2003116907A (en) | External use lesion protective material | |
RU2790927C1 (en) | Micrografting method in closing infected wounds of soft tissues | |
RU2176513C1 (en) | Wound-healing plate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): DK FI JP NO US |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1983902918 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 841936 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1983902918 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1983902918 Country of ref document: EP |